Research Interests
The group headed by Feng Wenhua focuses on the research and development of new drugs based on the needs of patients, such as the development of rare disease drugs, new antibiotics against drug-resistant bacteria; research on peptides and nucleic acid drugs, etc.
Their research covers:
1. Development of rare disease drugs
The development of 8 rare disease drugs has been completed, and strategic cooperation agreements have been reached with related companies. Two varieties of Vigabatrin and Carglumic Acid have entered the priority review stage
2. Development of new antibiotics against drug-resistant bacteria
Structure optimization of vancomycin derivatives and tetracycline derivatives has been carried out respectively, and the structure-activity relationship has been further clarified. In particular, three vancomycin-like lead compounds were found, which have significant antibacterial activity and good safety, and further evaluation of drug formation is needed.
3. Research on peptides and nucleic acid drugs
Based on the needs of clinical drugs, the development of non-patented peptide and nucleic acid drugs and the research of innovative drugs are carried out. The synthesis process research of 1 peptide drug and 1 nucleic acid drug has been completed.
